These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19654294)

  • 21. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
    Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
    Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
    Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
    PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis.
    Haber DA
    Cell; 2003 Nov; 115(5):507-8. PubMed ID: 14651841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new assay for functional screening of BRCA2 linker region mutations identifies variants that alter chemoresistance to cisplatin.
    Warren CR; Catts ZA; Farach-Carson MC
    Exp Cell Res; 2011 Sep; 317(15):2099-109. PubMed ID: 21741379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
    Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
    Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
    Bar JK; Harłozińska A; Popiela A; Noga L
    Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?
    Osher DJ; Kushner YB; Arseneau J; Foulkes WD
    J Clin Pathol; 2011 Oct; 64(10):924-6. PubMed ID: 21378390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.
    Hughes-Davies L; Huntsman D; Ruas M; Fuks F; Bye J; Chin SF; Milner J; Brown LA; Hsu F; Gilks B; Nielsen T; Schulzer M; Chia S; Ragaz J; Cahn A; Linger L; Ozdag H; Cattaneo E; Jordanova ES; Schuuring E; Yu DS; Venkitaraman A; Ponder B; Doherty A; Aparicio S; Bentley D; Theillet C; Ponting CP; Caldas C; Kouzarides T
    Cell; 2003 Nov; 115(5):523-35. PubMed ID: 14651845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade.
    Alblihy A; Ali R; Algethami M; Ritchie AA; Shoqafi A; Alqahtani S; Mesquita KA; Toss MS; Ordóñez-Morán P; Jeyapalan JN; Dekker L; Salerno M; Hartsuiker E; Grabowska AM; Rakha EA; Mongan NP; Madhusudan S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.
    Fajac A; Da Silva J; Ahomadegbe JC; Rateau JG; Bernaudin JF; Riou G; Bénard J
    Int J Cancer; 1996 Sep; 68(1):67-74. PubMed ID: 8895543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA.
    Chu E; Lai GM; Zinn S; Allegra CJ
    Mol Pharmacol; 1990 Sep; 38(3):410-7. PubMed ID: 2402230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
    Liu Y; Niu Z; Lin X; Tian Y
    Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
    Steffensen KD; Adimi P; Jakobsen A
    Int J Gynecol Cancer; 2017 Nov; 27(9):1842-1849. PubMed ID: 28763368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.